Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial

American Journal of Respiratory and Critical Care Medicine(2024)10.1164/rccm.202311-2004ocSource: DataRank Database

High-Dose Isoniazid Lacks EARLY Bactericidal Activity against Isoniazid-resistant Tuberculosis Mediated by katG Mutations: A Randomized Phase II Clinical Trial is a research paper published in American Journal of Respiratory and Critical Care Medicine (2024). On theSindex it has a DataRank of 0.741. It has been cited 13 times, with 12 citing works in its 1-hop citation network.

N/A

0.741DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access13 citations · 12 citing works in its network

Download PDF

Cite:

Linked data & code

gen nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT01936831

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (17 grants)Impact (FWCI 3.80)OA: greenTopics (50)IDs (PubMed, PMC, OpenAlex)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 53%Citation Network 47%

Base Score Contribution

0.396

From this paper's citation signal

Citation Network Contribution

0.345

From 8 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 12 citers.

Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Emerging infectious diseases20256 citations8 referencesContributes 0.243
Reconsidering the Role of Isoniazid in Drug-Resistant Tuberculosis
American Journal of Respiratory and Critical Care Medicine20242 citations14 referencesContributes 0.078
All‐Oral Shorter Treatment Regimens for Multidrug‐ and Rifampicin‐Resistant Tuberculosis: Evaluating Their Effectiveness, Safety, and Impact on the Quality of Life of Patients in Lao PDR
Tropical Medicine & International Health20251 citations34 referencesContributes 0.020
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists
Pathogens and Immunity202516 citations148 referencesContributes 0.019
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
Clinical Infectious Diseases20251 citations44 referencesContributes 0.016

Authors (19)

Elisa H. Ignatius ORCID,Veronique de Jager ORCID,Caryn M. Upton ORCID,Soyeon Kim ORCID,Ashley McKhann

Live enrichment

PubMed:38564365 PMC:PMC11348975 OpenAlex:https://openalex.org/W4393409028

National Institutes of Health

Grant: UM1 AI068634

National Institute of Allergy and Infectious Diseases

Grant: U01 AI068632

National Institute of Mental Health

Grant: AI068632

NIAID NIH HHS

Grant: K24 AI150349

NIAID NIH HHS

Grant: UM1 AI069432

NIAID NIH HHS

Grant: UM1 AI068632

NIAID NIH HHS

Grant: UM1 AI106701

NIGMS NIH HHS

Grant: T32 GM066691

NIAID NIH HHS

Grant: UM1 AI068636

NIAID NIH HHS

Grant: UM1 AI069421

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group

Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)

National Institute of Allergy and Infectious Diseases

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Infant Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT)

National Institute of Allergy and Infectious Diseases

FWCI

3.80

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: https://academic.oup.com/pages/standard-publication-reuse-rights

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11348975/pdf/rccm.202311-2004OC.pdf

publisherhttps://academic.oup.com/ajrccm/article-pdf/210/3/343/66996516/ajrccm_210_3_343.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11348975

journalhttps://doi.org/10.1164/rccm.202311-2004oc

Fields of Study

Tuberculosis Research and EpidemiologyCancer therapeutics and mechanismsHIV/AIDS drug development and treatmentIsoniazidHumansAntitubercular AgentsFemaleMaleTuberculosis, Multidrug-ResistantMycobacterium tuberculosisAdultMiddle AgedMutationBacterial ProteinsCatalaseDose-Response Relationship, DrugAgedMicrobial Sensitivity Tests

MeSH Terms

AdultAgedAntitubercular AgentsBacterial ProteinsCatalaseDose-Response Relationship, DrugFemaleHumansIsoniazidMaleMicrobial Sensitivity TestsMiddle AgedMutationMycobacterium tuberculosisTuberculosis, Multidrug-Resistant

Keywords

IsoniazidMedicineINHAMycobacterium tuberculosisTuberculosisPharmacologyDrug resistanceRifapentineRifampicinMicrobiologyLatent tuberculosisBiologyPathologyIsoniazid ResistancePhase 2 Clinical TrialEarly Bactericidal ActivityKatg Mutation

Sustainable Development Goals

SDG 0: Good health and well-being